64 related articles for article (PubMed ID: 38471524)
1. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.
Chatzilygeroudi T; Chondrou V; Boers R; Siamoglou S; Athanasopoulou K; Verigou E; Gribnau J; Alexis S; Labropoulou V; Kourakli A; Patrinos GP; Sgourou A; Symeonidis A
Clin Epigenetics; 2024 Jun; 16(1):79. PubMed ID: 38879530
[TBL] [Abstract][Full Text] [Related]
2. Demethylating agents in myeloid malignancies.
Garcia-Manero G
Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
[TBL] [Abstract][Full Text] [Related]
3. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
[TBL] [Abstract][Full Text] [Related]
4. [Epigenetic dysregulation and emerging treatment strategies in myelodysplastic syndromes].
Kunimoto H
Rinsho Ketsueki; 2024; 65(5):362-374. PubMed ID: 38825515
[TBL] [Abstract][Full Text] [Related]
5. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
Gill H
Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
[TBL] [Abstract][Full Text] [Related]
6. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract][Full Text] [Related]
7. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
[TBL] [Abstract][Full Text] [Related]
9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
10. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
